Abstract:Background: Preeclampsia (PE) is associated with subsequent higher risk of cardiovascular and kidney disease. Serum copeptin, as a proxy for vasopressin, and urinary uromodulin, were associated with PE physiopathology and kidney functional mass respectively. We describe concentrations of these proteins in the post-partum period and characterize their association with persistent hypertension (HTN) or albuminuria. Methods: Patients with PE and healthy controls with uncomplicated pregnancy were prospectively included at two teaching hospitals in Switzerland. Clinical parameters along with serum copeptin and urinary uromodulin were measured at 6 weeks post-partum. PE patients were further characterized based on presence of HTN (defined as either systolic BP (SBP) ≥140 mmHg or diastolic (BP) ≥90 mmHg) or albuminuria [defined as urinary albumin to creatinine ratio (ACR) ≥3 mg/mmol]. Results: We included 226 patients with 35 controls, 120 (62.8%) PE with persistent HTN/albuminuria and 71 (37.1%) PE without persistent HTN/albuminuria. Median serum copeptin concentration was 4.27 (2.9–6.2) pmol/L without differences between study groups ( p > 0.05). Higher copeptin levels were associated with higher SBP in controls ( p = 0.039), but not in PE ( p > 0.05). Median urinary uromodulin concentration was 17.5 (7.8–28.7) mg/g with lower levels in PE patients as compared to healthy controls ( p < 0.001), but comparable levels between PE patients with or without HTN/albuminuria ( p > 0.05). Higher uromodulin levels were associated with lower albuminuria in PE as well as control patients ( p = 0.040). Conclusion: Serum copeptin levels at 6 weeks post-partum are similar between PE patients and healthy controls and cannot distinguish between PE with or without residual kidney damage. This would argue against a significant pathophysiological role of the vasopressin pathway in mediating organ damage in the post-partum period. On the opposite, post-partum urinary uromodulin levels are markedly lower in PE patients as compared to healthy controls, potentially reflecting an increased susceptibility to vascular and kidney damage that could associate with adverse long-term cardiovascular and kidney outcomes.

EP12.05: Correlation between angiogenetic biomarkers, urinary protein values and ascites in women with hypertensive disorders of pregnancy

EP12.03: Circulating angiogenic factors levels in women with hypertensive disorders of pregnancy according to the baseline hemodynamic findings

EP17.54: Assessment of the angiogenic ratio versus glycosylated fibronectin in predicting adverse neonatal outcome in women with suspected pre‐eclampsia

EP17.06: Inter‐manufacturer assessment of the diagnostic performance of angiogenic ratio versus glycosylated fibronectin in women with suspected pre‐eclampsia

Angiogenic markers and maternal echocardiographic indices in women with hypertensive disorders of pregnancy

OP13.05: Assessment of the angiogenic ratio versus glycosylated fibronectin in predicting adverse maternal outcome in women with suspected pre‐eclampsia

Effective Prediction of Preeclampsia by Measuring Serum Angiotensin II, Urinary Angiotensinogen and Urinary Transforming Growth Factor Β1.

P182 AORTIC VASCULAR BIOMARKERS FOR THE EARLY DETECTION OF PLACENTAL SYNDROMES DURING PREGNANCY: A SYSTEMATIC REVIEW AND META-ANALYSIS

EP12.14: Postpartum sonographic measurement of the inferior vena cava and correlation with hemoglobin levels

EP01.56: Postpartum remote blood pressure monitoring and risk of hypertensive related readmission: systematic review and meta‐analysis of RCTs

A longitudinal study on the effect of obesity upon circulating renin-angiotensin system in normal pregnancy

Association of serum copeptin and urinary uromodulin with kidney function, blood pressure and albuminuria at 6 weeks post-partum in pre-eclampsia

EP17.27: Prognostic value of maternal N‐terminal pro‐B‐type natriuretic peptide for prediction of adverse maternal outcomes in women with pre‐eclampsia

EP12.07: Contribution of circulating neutrophil extracellular traps to endothelial dysfunction in pre‐eclampsia

Platelet indices and angiogenesis markers in hypertensive disorders of pregnancy

EP17.70: Outcome of acute kidney injury secondary to hypertensive complications of pregnancy

EP12.08: Risk of superimposed pre‐eclampsia and adverse outcomes in pregnant women with chronic hypertension

Correlation of 24-h Urinary Protein Excretion, Serum Indicators, and Placental Growth Factor in Patients with Preeclampsia and their Adverse Outcome

OC02.03: *Correlation of angiogenic factors PlGF and sFlt‐1 with severity stages of fetal growth restriction

EP11.24: Management of a high‐risk pregnancy associating autoimmune diseases, chronic hypertension, prediabetes and inherited thrombophilia

EP17.24: Maternal ophthalmic artery Doppler in normal pregnancy and pre‐eclampsia and its association with pregnancy outcome